Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aprea Therapeutics (Nasdaq: APRE) reported financial results for 2022, highlighting its focus on developing cancer therapeutics targeting DNA damage response pathways. The company initiated its Phase 1/2a clinical trial for ATR inhibitor ATRN-119 and secured approximately $5.5 million from a public offering to extend its cash runway to Q3 2024. Cash and equivalents stood at $28.8 million as of December 31, 2022. Aprea experienced a reduced operating loss of $2.7 million in Q4 2022, down from $7.8 million in Q4 2021. The year-end net loss was $112.7 million, a significant increase from $37.1 million in 2021, primarily due to acquired in-process research and development costs.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the selection of its abstract on preclinical programs ATRN-119 and ATRN-W1051 for presentation at the AACR 2023 Annual Meeting in Orlando, Florida, scheduled for April 14-19, 2023. The poster, titled 'ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment,' will be presented on April 19 at 9:00 am ET, focusing on DNA damage response pathways in cancer treatment. Aprea is committed to developing synthetic lethality cancer therapeutics, with ATRN-119 currently in clinical stages for solid tumors and plans for WEE1 inhibitor IND submission.
Aprea Therapeutics, a biopharmaceutical company focused on cancer therapeutics, announced that CEO Oren Gilad will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The presentation will provide a corporate overview and will be accessible via a live webcast on the company's website, followed by a replay available for 90 days. Aprea is developing innovative drugs targeting DNA damage response pathways, with its lead program being ATRN-119, aimed at treating solid tumors. The company emphasizes its commitment to disclosing material information via its investor relations platform.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Select Market. This achievement follows a recent financing round supported by quality institutions, which strengthened its balance sheet. Aprea is focused on developing cancer therapeutics targeting DNA damage response pathways, with its lead program being ATRN-119, currently in clinical trials. The company is also advancing a WEE1 inhibitor toward IND submission.